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1. Introduction
Rising life expectancy results in an increase of degenerative and neoplastic diseases. Popula‐
tion-based observational studies report that 1% to 2% of patients older than 65 years have
moderate-to-severe aortic stenosis (AS) [1]. Surgical aortic valve replacement (AVR) dates
back to 1960 and is currently the only treatment option for severe AS that has been shown to
improve survival, regardless of age [2]. In the ideal candidate, surgical AVR has an estimat‐
ed operative mortality of 4% [2]. Unfortunately, up to one-third of patients with severe AS
are ineligible for corrective valve surgery, either because of advanced age or the presence of
multiple comorbidities [3]. Current treatment options for those patients not offered surgery
include medical treatment or percutaneous balloon aortic valvuloplasty, although neither
has been shown to reduce mortality. Medically treated patients with symptomatic AS have
1- and 5-year survival of 60% and 32%, respectively [4,5]. With the introduction of percuta‐
neous aortic valve implantation in 2002, there seems to be an alternative for these patients.
2. Selection of patient
Due to the existence of tried and tested surgical AVR with good long-term results, the selec‐
tion of patients for transcatheter aortic valve implantation (TAVI), which should done in a
multidisciplinary consultation between cardiologists, surgeons, imaging specialists, and an‐
esthesiologists, involves several critical steps [6]. Candidates considered for TAVI must have
severe symptomatic AS in addition to a formal contraindication to surgery or other charac‐
teristics that would limit their surgical candidacy because of excessive mortality or morbidi‐
© 2013 Akin et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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ty (Figure 2). The procedure should be offered to patients who have a potential for
functional improvement after valve replacement. It is not recommended for patients who
simply refuse surgery on the basis of personal preference.
Figure 1. Algorithm to determine the treatment options of patients with severe AS (AVA: aortic valve area; TAVI:
transcatheter aortic valve implantation)
3. Confirming the severity of aortic stenosis
Actually, TAVI is indicated only for patients with calcified pure or predominant sympto‐
matic AS. The different imaging modalities can assist in the selection process by providing
important information on the aortic valve, coronary arteries, and vascular structures. First,
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the severity of AS should be assessed. Both transthoracic (TTE) and transesophageal (TEE)
Doppler echocardiography are the preferred tools (Figure 2).
Figure 2. TTE in the assessment of severe AS
In addition, the exact anatomy of the aortic valve should be assessed. Echocardiography,
multislice CT (MSCT), and magnetic resonance imaging (MRI) can all help to distinguish be‐
tween a bicuspid and a tricuspid aortic valve. It is important to point out that implantation
of available percutaneous prostheses is contraindicated in the case of a bicuspid aortic valve,
because of the risk of incomplete deployment, significant paravalvular regurgitation, and
displacement of the prosthesis [6,7] (Figure 3).
Figure 3. ECG-gated CT-scan in a patient with severe aortic valve stenosis (the upper right panel shows the isolated
calcification of the tricuspid aortic valve)
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A severely calcified aortic valve may result in the inability to cross the native valve with the
catheter. Bulky leaflets and calcifications on the free edge of the leaflets may increase the
risk of occlusion of the coronary ostia during aortic valve implantation. Therefore, the extent
and exact location of calcifications should be carefully assessed before the implantation pro‐
cedure. Assessing coronary anatomy is also important in the selection process. Conventional
coronary angiography, which remains the “gold standard”, should be done to exclude the
presence of significant coronary artery disease (Figure 4).
Figure 4. Invasive diagnostic prior TAVI, including aortography and access vessels as well as transvalvular gradient
4. Analysis of surgical risk and evaluation of life expectancy and quality
of life
The precise evaluation of surgical risk in a specific patient is not easy and involves an at‐
tempt at individualization based on statistical data from databases containing a large num‐
ber of procedures. The most accepted and validated algorithms that are widely available
today are the EuroSCORE, the STS (Society of Thoracic Score) score,and the Parsonnet score.
These algorithms predict the surgical risk by assigning weight to various factors that affect
the clinical result, but it is clear that they can underestimate or overestimate the risk in cer‐
tain groups of patients who are not represented satisfactorily in the population used to gen‐
erate the algorithm [8]. There is some evidence in the literature of the incorrect prediction of
aortic AVR outcome using the EuroSCORE model [9]. The key element for establishing
whether patients are at high risk for surgery is multidisciplinary clinical judgment, which
should be used in association with a more quantitative assessment, based on the combina‐
tion of several scores (for example, expected mortality >20% with the EuroSCORE and >10%
with STS score). This approach allows the team to take into account risk factors that are not
covered in scores but often seen in practice, such as chest radiation, previous aortocoronary
bypass with patent grafts, porcelain aorta, liver cirrhosis.
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5. Assessment of feasibility and exclusion of contraindications for TAVI
After criteria of severe symptomatic aortic valve stenosis and high surgical risk are evaluat‐
ed, the technical evaluation of the patient’s suitability for the percutaneous implantation
technique begins (Table 1).
Indication for Transcatheter aortic valve implantation
Severe aortic stenosis (AVA: <1cm2,mean gradient "/>40mmHg, severe symptoms) 
Contraindication for surgical valve replacement
Contraindication for Transcatheter aortic valve implantation
Mild to moderate aortic stenosis
Asymptomatic patients
Life expectancy <1 year
Surgical aortic valve replacement possible, but patient refused
Aortic anulus <18 or "/>25mm (balloon-expandable) and <20 or "/>27mm (self-expandable)
Bicuspid aortic valve
Asymetric heavy valvular calcification
Aortic root "/>45mm at the aortotubular junction
Presence of left ventricular apical thrombus
Contraindication for transfemoral approach
Severe calcification, tortuosity, small diameter of the iliac arteries
Previous aortofemoral bypass
Severe angulation, severe atheroma of the aorta
Coarctation of the aorta
Aneurysm of the aorta with protruding mural thrombus
Contraindication for transapical approach
Previous surgery of the left ventricle using a patch
Calcified pericardium
Severe respiratory insufficiency
Non-reachable left ventricular apex
Table 1. Actually proposed indications and contraindications for TAVI
The two most basic parameters are the suitability of the peripheral arteries and the size of
the aortic valve annulus. Contrast angiography is needed to assess the former, while the lat‐
ter requires an initial assessment of the diameter of the aortic annulus on a TTE. In general
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terms, a large artery with dominant elastic elements should have a diameter up to 1 mm
smaller than the external diameter of the sheath that has to be introduced for the valve im‐
plantation. Thus, current systems with an external sheath diameter of 28 F (SAPIEN 26 mm,
Edwards Lifescience LLC, Irvine, CA), 25 F (SAPIEN 23 mm, Edwards) and 22 F (CoreValve,
Medtronic, Inc., Minneapolis, MN) require minimum diameters of 8, 7, and 6 mm, respec‐
tively. Apart from the minimum diameter, the existence of significant vessel tortuosity
(>90°), especially when combined with wall calcifications, makes advancing the large sheath
problematic, with a high risk of vascular complications that could potentially affect the final
outcome. In addition, the existence of extensive circumferential calcifications limits the elas‐
tic dilation of the artery; thus, the minimum diameters referred to above are underestimat‐
ed. Patients who do not meet the criteria of suitable peripheral arterial access may still be
candidates for transapical implantation. For the assessment of aortic annulus diameter, we
should keep in mind that TTE underestimates its size by a mean of 1.4 mm compared with
TEE [6,10], while the latter method also underestimates the size by 1.2 mm compared with
intraoperative measurement [10]. Therefore, in order to avoid undesirable and often cata‐
strophic displacement of the prosthesis, there should be a margin of at least 1-2 mm between
the diameter of the valve and the size of the aortic annulus estimated using TEE, so that the
former may be successfully and safely anchored within the latter. Computed tomography
scan aortography and angiography of the ascending aorta are the most appropriate exami‐
nations for investigating these aspects. Those examinations will also be used for the meas‐
urement of the dimensions of the ascending aorta and the aortic arch, which are essential for
checking eligibility for the CoreValve (the most important being the diameter of the ascend‐
ing aorta, which should be <4.3 cm) (Figure 5).
Figure 5. ECG-gated CT-scan of a patient with severe aortic valve stenosis and porcelain aorta after radiation exposure
The anatomy of the thoracic aorta (any chance of porcelain aorta) and the abdominal aorta
should be studied by some imaging method for the existence of extensive atheromatosis,
mural thrombi and aneurysm (Figure 6).
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Figure 6. Three-dimensional reconstruction of contrast-enhanced CT angiography to assess morphology of femoral
arteries (left) and centerline stretched view (right)
6. Different transcatheter aortic valves
On the basis of first results from clinical trials, CoreValve Revalving System and Edwards
Lifescience SAPIEN obtained CE mark approval in 2007 with the specification that these
valves are intended for patients with a high or prohibitive risk for surgical valve replace‐
ment or who cannot undergo AVR. The first generation balloon-expandable valve was enti‐
tled Cribier-Edwards valve (Edwards Lifesciences), whereas at present the Edwards
SAPIEN valve (Edwards) is commercially available (Figure 7). The Edwards Lifesciences
SAPIEN THV device is a balloon-expandable valve. It consists of bovine pericardium that is
firmly mounted within a tubular, slotted, stainless steel balloon-expandable stent. Two
valve sizes have been developed (23mm and 26mm). At present, available prosthesis sizes
are 23 and 26 mm for aortic annulus diameters between 18–22 mm and 21–25 mm, respec‐
tively. The CoreValve Revalving device is a self-expanding frame-valve prosthesis (Figure
7). It consists of a porcine pericardial tissue valve that is mounted and sutured in a multile‐
vel self-expanding nitinol frame. It is available in 26, 29 and 31 mm sizes. The device has a
broader upper segment (outflow aspect), which yields proper orientation to the blood flow.
The first-generation valve used bovine pericardial tissue and was constrained within a 25
French (F) delivery catheter. The second-generation valve was built with porcine pericardial
tissue within a 21 F catheter to allow access through smaller-diameter vascular beds. The
third-generation of the device features a catheter with a valve delivery sheath size of 18 F
and a follow-on shaft of 12 F.
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Figure 7. Profile of the CoreValve Revaving System (A) and Edwards SAPIEN Transcatheter Heart Valve (B)
Newer  devices  that  have  first-in-man  application  include  Paniagua  (Endoluminal  Tech‐
nology  Research,  Miami,  FL),  Enable  (ATS,  Minneapolis,  MN),  AoTx  (Hansen  Medical,
Mountain View, CA),  Perceval  (Sorin Group,  Arvada,  CO),  Jena (JenaValve Technology,
Wilmington, DE), Lotus Valve (Sadra Medical,  Campbell,  CA), and Direct Flow percuta‐
neous aortic valve (Direct Flow Medical, Inc., Santa Rosa, CA). TAVI represents a unique
challenge for anesthesiologists. As with other invasive procedures, a careful preoperative
assessment, appropriate intraoperative monitoring and imaging, meticulous management
of hemodynamics, and early treatment of expected side effects and complications is of ut‐
most importance. An unexpected decrease or increase in systemic vascular resistance re‐
sulting  in  decreased coronary  perfusion  pressure  or  acute  heart  failure  by  elevated  left
ventricular  end-diastolic  pressure  should  be  avoided  by  maintaining  a  normotensive
blood pressure  and  heart  rate  between  60  bpm and 100  bpm.  The  choice  of  anesthetic
technique, either local anesthesia with mild sedation promoting spontaneous respiration,
deep intravenous sedation with insertion of a laryngeal mask, or general anesthesia, var‐
ies  among  centers  and  is  probably  not  associated  with  a  significant  difference  in  out‐
come.  Post  valvuloplasty  and  implantation,  which  were  done  under  rapid  right
ventricular pacing due to reduce left ventricular ejection and cardiac motion, may require
some additional inotropic support. Tracheal extubation can usually be done at the end of
the  procedure.  Close  postoperative  monitoring is  necessary,  and admission to  an inten‐
sive care unit is required. However, at present a retrograde approach through the femo‐
ral artery is used. During the procedure, a balloon valvuloplasty is first done to facilitate
passage of the native aortic valve. During rapid right ventricular pacing, the prosthesis is
positioned and deployed under fluoroscopy and echocardiographic guidance. Alternative‐
ly, in patients with difficult vascular access because of extensive calcifications or tortuosi‐
ty  of  the  femoral  artery  or  aorta,  a  transapical  approach  can  be  used.  After  a  partial
thoracotomy, direct puncture of the apical portion of the left ventricular free wall is done
to gain catheter access to the left ventricle and aortic valve. The prosthesis is subsequent‐
ly positioned and deployed, similar to the antegrade approach.
Calcific Aortic Valve Disease490
7. Implantation approaches
With regard to the delivery systems and their introduction into ascending aorta, two specific
pathways have been explored so far: the antegrade pathway, which uses direct transapical
access, and the retrograde pathway, which uses either transfemoral or trans-subclavian or
trans-axillary access [11].
7.1. The transapical approach
The main advantages of using transapical procedures are: [1] the feasibility does not rely on
the absence of a concomitant peripheral vascular disease or previous aortic surgery; [2] the
delivery system seems to be more “steady” and the procedure itself more “straightforward”;
and [3] this access potentially reduces the risk of calcium dislodgement due to the passage
of a stiff transfemoral device into a diseased aortic arch. A transapical approach can be used
in the operating room, in a hybrid room, or in a catheterization laboratory with a patient un‐
der general anesthesia. Regardless of where the transapical approach is done, it is a prereq‐
uisite that high-quality fluoroscopic imaging must be guaranteed. Apical bleeding is very
rare, mostly related to patient tissue fragility or to the team learning curve, and represents
the most dangerous complication related to transapical access itself. In transapical TAVI, the
cardiac apex is prepared through a small left anterolateral mini-thoracotomy using a purse-
string or a crossing suture reinforced by pledgets and, after the procedure, a chest tube is
routinely inserted into the left pleura with pain releasers injected in the intercostal tissue
(Figure 8).
Figure 8. TAVI using the transapical approach
7.2. The transfemoral approach
The transfemoral approach is used mostly in cardiac catheterization laboratory or a hybrid
room. One of the main advantages of this technique is that it allows fully percutaneous im‐
plantation in conscious patients, as long as the peripheral vessels are of an adequate caliber
(more than 6mm diameter), there are no very tortuous vessels, and vascular closure devices
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are available (Figure 9). Alternatively, the standard technique requires surgical preparation
of the common femoral artery under local or general anesthesia. Major and minor postoper‐
ative vascular complications have been reported quite often in recent series [12,13] and some
critical events (vessel dissections, ruptures or avulsions) might be catastrophic when not
promptly and adequately treated.
 
Figure 9. TAVI using the transfemoral approach
7.3. The trans-subclavian approach
Trans-subclavian access is an alternative retrograde pathway that has been recently ex‐
plored. It requires a surgical exposure of the left subclavian artery and an adequate minimal
vessel inner diameter for 18F delivery systems (Figure 10). There are some advantages in us‐
ing this approach: firstly, the distance between the site of introduction and the aortic valve is
short, compared with the transfemoral option, and it results in a steadier pathway. Second‐
ly, as long as the subclavian artery is intact, the trans-subclavian procedure can be done in
case of a concomitant vascular disease involving the abdominal aorta or the legs, and it does
not require a thoracotomy. Unfortunately, the presence of a patent internal mammary ar‐
tery, such as a diseased subclavian artery, in redo coronary surgery contraindicates this ap‐
proach. However, at this moment, this interesting approach remains “off-label” and is not
yet formally recommended by the industry.
 
Figure 10. TAVI using the subclavian approach
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7.4. The trans-aortic approach
In case of severe vascular disease and a concomitant contraindication to transapical proce‐
dures, an alternative, interesting, retrograde approach has been proposed: through an upper
“J-shape” mini-sternotomy, the guidewire and the delivery system are inserted, retrograde‐
ly, into the ascending aorta and are secured with a double-string suture. TAVI is then done
as a transfemoral procedure. The presence of “porcelain” aorta and the risk of postoperative
massive bleeding limit this approach to selected patients.
8. Results from the literature
8.1. Cribrier-Edwards valve
Cribier et al. did the first human implantation in 2002 [14]. The Edwards SAPIEN valve was
approved for use in the European Union in November 2007 (for the transfemoral approach)
and in January 2008 (for transapical delivery). In the Initial Registry of EndoVascular Im‐
plantation of Valves in Europe (I-REVIVE) trial, followed by the Registry of Endovascular
Critical Aortic Stenosis Treatment (RECAST) trial, a total of 36 patients (mean (SD) Euro‐
SCORE 12 (2)) were included [15]. Twenty-seven patients underwent successful percutane‐
ous aortic valve implantation (23 antegrade, 4 retrograde). The 30-day mortality was 22% (6
of 27 patients), and the mean AVA increased from 0.60 ± 0.11cm2 to 1.70 ± 0.10cm2
(p<0.001). Importantly, this improvement in AVA was maintained up to 24 months follow-
up [16]. Since these first trials, the Cribrier-Edwards prosthesis and the Edwards SAPIEN
prosthesis have been used in numerous studies. Overall, acute procedural success is ach‐
ieved in 75–100% of the procedures, and 30-day mortality ranges between 8–50% in the pub‐
lished studies. Using the transapical technique and the Sapien valve, Walther et al. [17] has
reported their initial multicenter results of 59 consecutive patients, which is the largest feasi‐
bility study published thus far. Procedural success using the transapical technique was ach‐
ieved in 53 patients. Thirty-day mortality was 13.6% and none of these were thought to be
valve related as there was good valve function at autopsy. The overall procedural success of
1038 SAPIEN implants from 32 centers within the European SOURCE registry was 93.8%.
The 30-day survival within SOURCE was 93.7% (transfemoral) and 89.7% (transapical) [18].
The 1-year survival of the cohort was 81.1% (transfemoral) and 72.1% (transapical), respec‐
tively. In cohort B of the PARTNER randomized trial, 179 patients receiving transfemoral
SAPIEN aortic valve with 179 patients receiving standard medical therapy (including bal‐
loon aortic valvuloplasty), confirmed the superiority of transfemoral TAVI with regard to
overall survival and cardiac functional status [19]. The Kaplan-Meier 1-year mortality from
any cause was 30.7% (TAVI) versus 50.7% (standard medical therapy), corresponding to a
0.55 hazard ratio with TAVI (p<0.001). The fraction of surviving patients at 1-year, in New
York Heart Association functional class III-IV, was lower in the TAVI group (25.2% versus
58%; p<0.001). Nevertheless, the TAVI group had a higher 30-day incidence of major stroke
(5.0% versus 1.1%; p=0.06) and major vascular complications (16.2% versus 1.1%; p<0.001).
Early and 1-year outcomes from the REVIVAL trial, which consisted of 55 patients with a
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mean AVA of 0.57±0.14cm2 and a mean logistic EuroSCORE of 33.5±17%, have been report‐
ed [20]. TAVI was successful in 87%. Mean echocardiographic AVA improved from 0.56±14
to 1.6±0.48cm2 after the procedure (p<0.0001). Thirty-day all-cause mortality and major ad‐
verse cardiac events (MACE) were 7.3% and 20%, respectively. These rates increased to
23.6% and 32.7%, respectively, at 1 year, with most late events related to underlying comor‐
bidities. The mean NYHA functional class improved from 3.22±0.66 at baseline to 1.50±0.85
at 1-year follow-up (p<0.001).
8.2. CoreValve ReValving
Since the first implantation of the CoreValve prosthesis in a patient in 2005 [12], a large
number of patients have been treated with this device. The feasibility and safety of this
valve was studied in a prospective, multicenter trial [12]. A total of 25 symptomatic patients
with an AVA < 1cm2 were enrolled in the study. The device was successfully implanted us‐
ing the retrograde technique in 22 of 25 patients. Procedural success and aortic mean pres‐
sure gradients were markedly improved immediately following implantations with pre-
procedure gradients 44.24 ± 10.79 mmHg to 12.38 ± 3.03 mmHg post-procedure, and were
about the same at 30-day follow-up (11.82 ± 3.42 mm Hg). NYHA functional class improved
by 1 to 2 grades in all patients. MACE, defined as death from any cause, major arrhythmia,
myocardial infarction, cardiac tamponade, stroke, urgent or emergent conversion to surgery
or balloon valvuloplasty, emergent percutaneous coronary intervention, cardiogenic shock,
endocarditis, or aortic dissection, occurred in 8 of the 25 hospitalized patients. Recently,
Grube et al. [21] reported the results with the three different generations of the CoreValve
Revalving system in a non-randomized, prospective study of 136 patients. Ten patients were
treated with first-generation devices, 24 patients with second-generation, and 102 patients
with third-generation devices. At baseline, mean AVA was 0.67cm2 and mean logistic Euro‐
SCORE was 23.1% in the overall study population. With the new-generation devices, the
overall procedural success rate significantly increased from 70.0% and 70.8% to 91.2% for
the first-, second-, and third-generation prostheses, respectively (p = 0.003). Interestingly, us‐
ing newer devices, periprocedural mortality decreased from 10% (first-generation) to 8.3%
(second-generation) to 0% (third-generation). Overall 30-day mortality for the three genera‐
tions was 40%, 8.3% and 10.8%, respectively. Pooled data demonstrated a significant im‐
provement in mean NYHA functional class (from 3.3 to 1.7, p<0.001), without a difference
between the three generations. Importantly, NYHA functional class and mean pressure gra‐
dient remained stable up to 12 months follow-up in all three generations. In addition, the
results of a multicenter registry with the third-generation CoreValve Revalving system have
recently been reported [22]. A total of 646 patients from 51 centers were included in the reg‐
istry. It was a high-risk elderly population (mean age: 81 years) with a poor functional class
(85% of the patients in NYHA class III or IV), and a high logistic EuroSCORE (mean: 23.1%).
Procedural success was achieved in 628 of the 646 patients (97.2%). All-cause 30-day mortali‐
ty was 8%, and the combined end point of procedural related death, stroke, or myocardial
infarction was reached in 60 patients (9.3%). After successful implantation, mean pressure
gradient decreased from 49 mmHg to 3 mmHg [22]. The FRANCE real-world registry of 244
consecutive high-risk patients with symptomatic severe AS, enrolled from 16 centers over a
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period of 5 months in 2009, reported 98.3% procedural success for both Edwars SAPIEN and
Medtronic CoreValve (66% transfemoral, 5% subclavian, and 29% transapical) prostheses
[13]. The 30-day mortality was 12.7%, and, at 1 month, 88% of patients were in NYHA class
I-II. Buellesfeld et al. [23] reported on a 2-year follow-up of 126 patients who underwent TA‐
VI. Thirty-day all-cause mortality was 15.2%. At 2-years, all-cause mortality was 38.1%, with
a significant difference between the moderate-risk group and the combined high-risk groups
(27.8% versus 45.8%; p=0.04). This difference was attributable to an increased risk of noncar‐
diac mortality in high-risk groups. Hemodynamic results remained unchanged during fol‐
low-up (mean gradient: 8.5±2.5mmHg at 30 days and 9.0±3.5mmHg at 2 years) without any
incidence of structural valve deterioration.
The larger CoreValve prostheses (26, 29 and 31 mm) were the only device for annulus be‐
tween 26 and 29 mm, before the currently available 29-mm SAPIEN XT valve for transapical
implantation. The CoreValve prosthesis had previously been the only device suitable for
transarterial implant in patients with limited iliofemoral artery access, but this has changed
with the SAPIEN NovaFlex delivery system. The growing experience with the subclavian
artery approach, however, allows the CoreValve prosthesis to be implanted in patients with
unusable iliofemoral arteries. Because of these results, the indications for TAVI expanded
(e.g. in patients with porcelain aorta, with previous cardiac surgery, etc.) [24] (Figure 11,12).
 
Figure 11. TAVI in a patient with a history of AVR
 
Figure 12. TAVI in a patient with a history of mitral valve replacement
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9. Conclusion
Transcatheter aortic valve implantation was developed to provide an alternative and less in‐
vasive method of treating aortic valve stenosis. Actually, it has been proved that the method
is feasible, with results that have been reproduced by many physicians in many centers (ap‐
proximately 10,000 implantations to date). Today there are at least 10 new transcatheter
aortic valves that have had their first implantation in humans, many more that have reached
the level of animal experiments, and even more that are still in the initial design stage. As a
new treatment tool, it has to be evaluated in randomized controlled trials with long-term
follow-up in order to assess safety and efficacy. Therefore, TAVI should be restricted to a
limited number of high-volume centers, that have both cardiology and cardiac surgery de‐
partments as well as expertise in structural heart disease intervention and high-risk valvular
surgery. Because of excellent results with surgical valve replacement, patient selection,
which should be done in multidisciplinary conferences, is of utmost importance. Like other
interventional procedures, there is a learning curve with significant improvements in the
success rate and the clinical results after the first 25 procedures, which implies that the TAVI
procedure should initially be done by and thereafter supervised by a special team [25,26]. In
addition to patient selection and intervention of TAVI, a close follow-up with assessment of
clinical and objective parameters is mandatory for defining the indications of this technique.
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